Dolby Laboratories, Inc. DLB
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -3.47%
- 1 year
- -5.59%
- Open
- 63.07
- Prev close
- 62.91
- Mkt cap
- 5.81B
- Vol
- 688.77K
- Avg vol
- 866.01K
- EPS
- 2.35
- P/E
- 26.38
- Div yield
- 2.29%
More statistics
- Low
- 61.54
- High
- 63.41
- Forward P/E
- 13.54
- Beta
- 0.78
- Short ratio
- 7.01
- Inst. own
- 107.47%
- Dividend
- 1.44
- Ex-div date
- Aug 10, 2026
- Earnings
- Nov 17, 2026
- 50-d avg
- 60.82
- 200-d avg
- 59.28
- 1y target
- 79.00
5D chart
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| RSI: Overbought | Oct 29, 11:55 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| RSI: Oversold | Oct 28, 2:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| RSI: Oversold | Oct 28, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:05 PM | 3 days ago |
| RSI: Oversold | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 5 days ago |
| RSI: Overbought | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:00 PM | 5 days ago |
| RSI: Oversold | Oct 26, 12:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 11:55 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 11:25 AM | 5 days ago |
| RSI: Oversold | Oct 26, 11:20 AM | 5 days ago |
| RSI: Oversold | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:30 AM | 5 days ago |
| RSI: Oversold | Oct 26, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 23, 3:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:30 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:10 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 3:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:50 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:45 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:30 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:25 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:20 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:50 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:50 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:35 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:25 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bearish | Oct 23, 11:05 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:55 AM | 1 week ago |
News
3 days ago globenewswire.com
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in…
1 month ago benzinga.com
Your Meta AI Glasses Are Getting a Dolby Upgrade
Meta expands Dolby Atmos & Vision across AI glasses, Instagram, and VR. Get the tech details and DLB stock forecast here.
3 months ago benzinga.com
Stock Market Today: Amazon Jumps 15%, Apple Wipes Out $475 Billion
Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.
3 months ago benzinga.com
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.
-
3 months ago benzinga.com
Dolby Laboratories Lowers FY2026 GAAP EPS Guidance from $2.66-$2.81 to $2.62-$2.77 vs $2.83 Est
Dolby Laboratories (NYSE:DLB) lowers FY2026 GAAP EPS guidance from $2.66-$2.81 to $2.62-$2.77 vs $2.83 analyst estimate..
-
3 months ago benzinga.com
Dolby Laboratories Lowers FY2026 Adj EPS Guidance from $4.30-$4.45 to $4.25-$4.40 vs $4.30 Est; Narrows FY2026 Sales Guidance from $1.400B-$1.450B to $1.410B-$1.440B vs $1.407B Est
Dolby Laboratories (NYSE:DLB) lowers FY2026 Adj EPS guidance from $4.30-$4.45 to $4.25-$4.40 vs $4.30 analyst estimate. Narrows FY2026 sales outlook from $1.400 billion-$1.450 billion to $1.410…
-
3 months ago benzinga.com
Dolby Laboratories Sees Q4 Adj EPS $1.13-$1.28 vs $1.20 Est; Sees Sales $362.000M-$392.000M vs $351.950M Est
Dolby Laboratories (NYSE:DLB) is looking for Q4 Adj EPS of $1.13-$1.28 vs $1.20 analyst estimate. sees sales of $362.000 million-$392.000 million vs $351.950 million analyst estimate.
-
3 months ago benzinga.com
Dolby Laboratories Q3 Adj. EPS $0.69 Beats $0.67 Estimate, Sales $304.995M Miss $311.960M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.67 by 2.99 percent. This is a 11.54 percent decrease over earnings of…
3 months ago benzinga.com
Top 3 Tech Stocks That May Rocket Higher In July
Find bargains in oversold IT stocks with RSI values below 30: Fabrinet (NYSE: FN), Dolby Laboratories (NYSE: DLB), Oracle Corp (NYSE: ORCL)
6 months ago benzinga.com
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU
U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.
6 months ago benzinga.com
Dolby Laboratories Q2 2026 Earnings Call: Complete Transcript
Dolby Laboratories Q2 2026 Earnings Call: Complete Transcript
6 months ago benzinga.com
12 Information Technology Stocks Moving In Thursday's After-Market Session
12 Information Technology Stocks Moving In Thursday's After-Market Session
-
6 months ago benzinga.com
Dolby Laboratories Sees Q3 Adj EPS $0.56-$0.71 vs $0.98 Est; Sees Sales $295.000M-$325.000M vs $343.538M Est
Dolby Laboratories (NYSE:DLB) is looking for Q3 Adj EPS of $0.56-$0.71 vs $0.98 analyst estimate. sees sales of $295.000 million-$325.000 million vs $343.538 million analyst estimate.
-
6 months ago benzinga.com
Dolby Laboratories Lowers FY2026 GAAP EPS Guidance from $2.71-$2.86 to $2.66-$2.81 vs $2.77 Est
Dolby Laboratories (NYSE:DLB) lowers FY2026 GAAP EPS guidance from $2.71-$2.86 to $2.66-$2.81 vs $2.77 analyst estimate..
-
6 months ago benzinga.com
Dolby Laboratories Affirms FY2026 Adj EPS Guidance of $4.30-$4.45 vs $4.33 Est; Affirms FY2026 Sales Guidance of $1.400B-$1.450B vs $1.417B Est
Dolby Laboratories (NYSE:DLB) affirms FY2026 Adj EPS guidance from $4.30-$4.45 to $4.30-$4.45 vs $4.33 analyst estimate. Affirms FY2026 sales outlook from $1.400 billion-$1.450 billion to $1.400…
-
6 months ago benzinga.com
Dolby Laboratories Q2 Adj. EPS $1.37 Beats $1.33 Estimate, Sales $395.630M Beat $385.801M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.33 by 3.01 percent. This is a 2.24 percent increase over earnings of $1.34…
6 months ago benzinga.com
Earnings Scheduled For April 30, 2026
Earnings Scheduled For April 30, 2026
-
9 months ago benzinga.com
Barrington Research Maintains Outperform on Dolby Laboratories, Maintains $90 Price Target
Barrington Research analyst Patrick Sholl maintains Dolby Laboratories (NYSE:DLB) with a Outperform and maintains $90 price target.
-
9 months ago benzinga.com
Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $85 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $85 price target.
-
9 months ago benzinga.com
Dolby Laboratories Raises FY2026 GAAP EPS Guidance from $2.61-$2.76 to $2.71-$2.86 vs $2.78 Est
Dolby Laboratories (NYSE:DLB) raises FY2026 GAAP EPS guidance from $2.61-$2.76 to $2.71-$2.86 vs $2.78 analyst estimate..
-
9 months ago benzinga.com
Dolby Laboratories Raises FY2026 Adj EPS Guidance from $4.19-$4.34 to $4.30-$4.45 vs $4.23 Est; Raises FY2026 Sales Guidance from $1.390B-$1.440B to $1.400B-$1.450B vs $1.406B Est
Dolby Laboratories (NYSE:DLB) raises FY2026 Adj EPS guidance from $4.19-$4.34 to $4.30-$4.45 vs $4.23 analyst estimate. Raises FY2026 sales outlook from $1.390 billion-$1.440 billion to $1.400…
-
9 months ago benzinga.com
Dolby Laboratories Sees Q2 Adj EPS $1.29-$1.44 vs $1.37 Est; Sees Sales $375.000M-$405.000M vs $379.185M Est
Dolby Laboratories (NYSE:DLB) is looking for Q2 Adj EPS of $1.29-$1.44 vs $1.37 analyst estimate. sees sales of $375.000 million-$405.000 million vs $379.185 million analyst estimate.
9 months ago benzinga.com
Dolby Laboratories: Q1 Earnings Insights
Dolby Laboratories: Q1 Earnings Insights
-
9 months ago benzinga.com
Dolby Laboratories Q1 Adj. EPS $1.06 Beats $0.88 Estimate, Sales $346.706M Beat $332.073M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $1.06 per share which beat the analyst consensus estimate of $0.88 by 20.87 percent. This is a 7.02 percent decrease over earnings of…
-
9 months ago benzinga.com
Earnings Scheduled For January 29, 2026
Earnings Scheduled For January 29, 2026
9 months ago benzinga.com
An Overview of Dolby Laboratories's Earnings
An Overview of Dolby Laboratories's Earnings
9 months ago benzinga.com
What Analysts Are Saying About Dolby Laboratories Stock
What Analysts Are Saying About Dolby Laboratories Stock
-
9 months ago benzinga.com
Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $85 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $85 price target.
-
9 months ago benzinga.com
From Flat To Full Immersion: The AWS Path To Dolby Vision And Dolby Atmos
https://aws.amazon.com/blogs/media/from-flat-to-full-immersion-the-aws-path-to-dolby-vision-and-dolby-atmos/
-
11 months ago benzinga.com
Rosenblatt Maintains Buy on Dolby Laboratories, Lowers Price Target to $85
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and lowers the price target from $95 to $85.
-
11 months ago benzinga.com
Dolby Laboratories Sees FY2026 Adj EPS $4.19-$4.34 vs $3.96 Est; Sees Sales $1.390B-$1.440B vs $1.347B Est
Dolby Laboratories (NYSE:DLB) is looking for FY2026 Adj EPS of $4.19-$4.34 vs $3.96 analyst estimate. sees sales of $1.390 billion-$1.440 billion vs $1.347 billion analyst estimate.
-
11 months ago benzinga.com
Dolby Laboratories Sees Q1 Adj EPS $0.79-$0.94 vs $1.14 Est; Sees Sales $315.000M-$345.000M vs $366.956M Est
Dolby Laboratories (NYSE:DLB) is looking for Q1 Adj EPS of $0.79-$0.94 vs $1.14 analyst estimate. sees sales of $315.000 million-$345.000 million vs $366.956 million analyst estimate.
-
11 months ago benzinga.com
Dolby Laboratories Q4 Adj. EPS $0.99 Beats $0.70 Estimate, Sales $307.024M Beat $304.695M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.70 by 41.43 percent. This is a 22.22 percent increase over earnings of…
11 months ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's After-Market Session
12 Information Technology Stocks Moving In Tuesday's After-Market Session
-
11 months ago benzinga.com
Earnings Scheduled For November 18, 2025
Earnings Scheduled For November 18, 2025
-
11 months ago benzinga.com
Enhancing HDR On Instagram For iOS With Dolby Vision
https://engineering.fb.com/2025/11/17/ios/enhancing-hdr-on-instagram-for-ios-with-dolby-vision/
11 months ago benzinga.com
Insights Ahead: Dolby Laboratories's Quarterly Earnings
Insights Ahead: Dolby Laboratories's Quarterly Earnings
-
1 year ago benzinga.com
Barrington Research Maintains Outperform on Dolby Laboratories, Maintains $100 Price Target
Barrington Research analyst Patrick Sholl maintains Dolby Laboratories (NYSE:DLB) with a Outperform and maintains $100 price target.
1 year ago benzinga.com
This Twilio Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Twilio Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
-
1 year ago benzinga.com
Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)
Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)
-
1 year ago benzinga.com
Baird Initiates Coverage On Dolby Laboratories with Neutral Rating, Announces Price Target of $74
Baird analyst Vikram Kesavabhotla initiates coverage on Dolby Laboratories (NYSE:DLB) with a Neutral rating and announces Price Target of $74.
1 year ago benzinga.com
Applied Materials To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
Applied Materials To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
-
1 year ago benzinga.com
Tigress Financial Maintains Buy on Dolby Laboratories, Raises Price Target to $114
Tigress Financial analyst Ivan Feinseth maintains Dolby Laboratories (NYSE:DLB) with a Buy and raises the price target from $112 to $114.
-
1 year ago benzinga.com
Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $95 price target.
-
1 year ago benzinga.com
Dolby Laboratories Affirms FY2025 Adj EPS Guidance of $3.88-$4.03 vs $3.97 Est; Narrows FY2025 Sales Guidance from $1.31B-$1.38B to $1.33B-$1.36B vs $1.34B Est
Dolby Laboratories (NYSE:DLB) affirms FY2025 Adj EPS guidance from $3.88-$4.03 to $3.88-$4.03 vs $3.97 analyst estimate. Narrows FY2025 sales outlook from $1.31 billion-$1.38 billion to $1.33…
-
1 year ago benzinga.com
Dolby Laboratories Sees Q4 Adj EPS $0.61-$0.76 vs $0.77 Est; Sees Sales $288.000M-$318.000M vs $310.12M Est
Dolby Laboratories (NYSE:DLB) is looking for Q4 Adj EPS of $0.61-$0.76 vs $0.77 analyst estimate. sees sales of $288.000 million-$318.000 million vs $310.12 million analyst estimate.
-
1 year ago benzinga.com
Dolby Laboratories Q3 Adj. EPS $0.78 Beats $0.71 Estimate, Sales $315.55M Beat $305.23M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.71 by 9.4 percent. This is a 9.86 percent increase over earnings of $0.71…
-
1 year ago benzinga.com
Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)
Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)
-
1 year ago benzinga.com
Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and maintains $95 price target.